Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...